Year: 2024

Financial Overview – Third QuarterRevenues of $278 Million, Up 100% From a Year Ago Adjusted Pre-Tax Income of $52 Million, GAAP Pre-Tax Income of $36 Million Adjusted EPS of $0.34; GAAP Diluted EPS of $0.24Financial Overview – Nine MonthsRevenues of $652 Million, Up 50% From a Year Ago Adjusted Pre-Tax Income of $97 Million, GAAP Pre-Tax Loss of $(96) Million Adjusted EPS of $0.69; GAAP Diluted EPS of $(1.61)Talent InvestmentYear-to-Date Added Five New Partners and Eleven New Managing DirectorsCapital ManagementStrong Balance Sheet with $335 Million of Cash, Cash Equivalents and Short-Term Investments and No Debt Year-to-Date Retired Approximately 12.3 Million Shares and Share Equivalents through Purchase, Exchange and Net Settlement Year-to-Date Returned $215 Million to Equity Holders Declared Quarterly Dividend...

All amounts in U.S. dollars unless otherwise indicated BROOKFIELD, News, Nov. 08, 2024 (GLOBE NEWSWIRE) — Brookfield Renewable Partners L.P. (TSX: BEP.UN; NYSE: BEP) (“Brookfield Renewable Partners”, “BEP“) today reported financial results for the three and nine months ended September 30, 2024. “We had another successful quarter highlighted by agreements to monetize several assets, crystallizing strong returns and generating significant funds to deploy into future growth. We also signed numerous favorable large-scale contracts within our North American hydro portfolio during the quarter that will enable us to execute upfinancings providing additional capital to invest in the current attractive environment,” said Connor Teskey, CEO of Brookfield Renewable. “These initiatives continue to demonstrate our sustainable...

Generated record quarterly net revenues of $148.3 million, representing year-over-year growth of 12.5%, and record Purified Cortrophin® Gel net revenues of $52.6 million, an increase of 76.8% year-over-year Net loss of $(24.2) million and adjusted non-GAAP EBITDA of $35.1 million Diluted GAAP loss per share of $(1.27) and adjusted non-GAAP diluted earnings per share of $1.34 Completed the acquisition of Alimera Sciences, Inc. on September 16, 2024, adding two commercial assets ILUVIEN® and YUTIQ® with significant growth potential to its Rare Disease portfolio Implemented new capital structure that is expected to reduce interest expense by approximately $39.0 million on an annualized basis (1) Increased 2024 guidance with expected net revenues of $594 million to $602 million, adjusted non-GAAP EBITDA of $149 million to $153 million and...

Conference Call and Webcast Today at 8:30 a.m. ETSubsequent to quarter-end, closed $30 million in debt financing OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) on track to complete enrollment in 1H2025 OCU410 is currently in Phase 2 of the Phase 1/2 ArMaDa clinical trial Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial approved enrollment for the second phase of the Phase 1/2 clinical trial New data on Phase 1/2 clinical trials for OCU410, OCU410ST and OCU400 to be presented at upcoming Clinical ShowcaseMALVERN, Pa., Nov. 08, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today reported third quarter 2024 financial...

BROOKFIELD, News, Nov. 08, 2024 (GLOBE NEWSWIRE) — Brookfield Business Partners (NYSE: BBU, BBUC; TSX: BBU.UN, BBUC) announced today financial results for the quarter ended September 30, 2024. “We had a good quarter, achieving solid financial results and generating over $350 million of proceeds from distributions and announced monetizations, including the sale of a significant portion of our offshore oil services operation,” said Anuj Ranjan, CEO of Brookfield Business Partners. “The progress we are making on our capital recycling initiatives will provide us significant liquidity to support our growth and with interest rates normalizing, we are in a great position to continue compounding value for investors.”  Three Months EndedSeptember 30,   Nine Months EndedSeptember 30,US$ millions (except per unit amounts), unaudited   2024       2023       2024       2023  Net...

Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024 Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan recognizing an upfront payment of $2.0 million in the fourth quarter of 2024 Achieved extension of primary DANYELZA U.S. patent through February 2034 Continued geographic expansion of DANYELZA with new market revenues recorded in the third quarter from Turkey Management reiterates Full Year 2024 guidance around Total Net Revenue, Operating Expenses, and Cash Flow Investment The Company will host a conference call on Friday, November 8, 2024, at 8:00 a.m. ETNEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development...

ATLANTA, Nov. 08, 2024 (GLOBE NEWSWIRE) — Gray Television, Inc. (“Gray,” “Gray Media,” “we,” “us” or “our”) (NYSE: GTN) today announced a strong third quarter ended September 30, 2024. Gray also projected full-year 2024 political advertising revenue of $500 million, as well as full-year 2024 Net Debt reduction of $500 million. SUMMARY OF THIRD QUARTER RESULTS OPERATING HIGHLIGHTS:Total revenue in the third quarter of 2024 was $950 million, an increase of 18% from the third quarter of 2023. Core advertising revenue in the third quarter of 2024 was $365 million, an increase of 1% from the third quarter of 2023. Retransmission consent revenue in the third quarter of 2024 was $369 million, a decrease of 2% from the third quarter of 2023. Political advertising revenue in the third quarter of 2024 was $173 million, an increase of 565%...

Third Quarter Revenue of $42.5 million, Net Loss of $6.0 million and Adjusted EBITDA of $4.7 million MIAMI BEACH, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) — AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced results for the third quarter and nine months ended September 30, 2024. “Our revenue and Adjusted EBITDA for the quarter were in line with our expectations with the period including progress on our strategy despite continued challenges in the consumer environment,” said Dennis Dean, Interim Chief Executive Officer and Chief Financial Officer of AirSculpt Technologies, Inc. “We are pleased with our four new center openings during the quarter and our 2023 de novo class continues to surpass our expectations. While our same center sales...

Three Month Results •  Net revenues was $564.1 million•  Net income was $147.8 million•  Adjusted EBITDA was $271.2 million Nine Month Results •  Net revenues was $1.63 billion•  Net income was $363.9 million•  Adjusted EBITDA was $754.6 million BATON ROUGE, La., Nov. 08, 2024 (GLOBE NEWSWIRE) — Lamar Advertising Company (the “Company” or “Lamar”) (Nasdaq: LAMR), a leading owner and operator of outdoor advertising and logo sign displays, announces the Company’s operating results for the third quarter ended September 30, 2024. “Our third quarter results came in largely as expected, with particular strength in local and programmatic sales. Expenses were slightly elevated but as we move through Q4, we see that correcting and see full year consolidated EBITDA margins coming in right around 47%,” chief executive Sean Reilly said. “In...